Clinical Trials
30 trialsNCT00733538 2024-04-12
IFM-01-04
Centre Hospitalier Universitaire de Nice
Phase 4 Completed
NCT02286830 2023-02-17
Magnolia
Odense University Hospital
Phase 4 Completed
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT00330759 2022-11-07
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
Amgen
Phase 3 Completed
NCT00622505 2021-05-26
Z-MARK
Novartis
Phase 4 Completed
NCT00424983 2020-12-21
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
Novartis
Phase 1 Completed
NCT01087008 2020-04-06
AZABACHE
PETHEMA Foundation
Phase 4 Completed
NCT01772719 2019-11-18
Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
University of Louisville
Phase NA Terminated
NCT00869206 2018-11-07
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00482378 2018-08-14
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain
Mayo Clinic
Phase 1/2 Completed
NCT01332617 2017-12-29
Phase II Study of Simvastatin for Relapsed/Refractory Myeloma
University of Louisville
Phase 2 Withdrawn
NCT00577642 2017-03-10
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
Massachusetts General Hospital
Phase 2 Completed
NCT00434447 2017-02-27
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT02739594 2016-07-22
COMPARE
Hoffmann-La Roche
Phase 3 Terminated
NCT00083382 2015-06-24
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
University of Arkansas
Phase 2 Completed
NCT00242528 2015-04-14
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
Novartis
Phase 4 Withdrawn
NCT00972959 2014-08-05
Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy
University of Athens
Phase 2 Completed
NCT00215943 2014-04-17
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
H. Lee Moffitt Cancer Center and Research Institute
Phase 3 Terminated
NCT00033332 2014-04-04
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00741377 2013-02-18
A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients
Novartis
Phase 1 Completed
NCT00258258 2013-02-01
Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders
Roswell Park Cancer Institute
Phase 1 Terminated
NCT00432458 2012-07-04
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
Mayo Clinic
Phase 3 Completed
NCT00171925 2012-04-11
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Novartis
Phase 3 Terminated
NCT00029224 2012-02-01
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Novartis
Phase 4 Completed
NCT00760370 2011-12-07
Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer
Vejle Hospital
Phase 2 Completed
NCT00263484 2011-07-21
dtZ
Gleneagles Hospital
Phase 2 Completed
NCT00104104 2011-06-29
A Multiple Myeloma Trial in Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT00216151 2011-05-02
Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT01341262 2011-04-25
THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase 2 Completed
NCT01234129 2010-11-04
Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma
Instituto Mexicano del Seguro Social
Completed